Afficher le profil
Base
| Nom | Nicolas LEPAREUR |
| Grade | |
| Equipe | |
| Adresse | CHU Pontchaillou – 2 rue Henri Le Guilloux – 35033 Rennes Cedex |
| Téléphone | |
| Skills | Radiochemistry; Organic and Coordination Chemistry; Nanoparticle formulation; Radiopharmaceuticals; Nuclear Medicine; Liver cancers. |
| Research topics and scientific objectives | Research interests include bioinorganic and radiopharmaceutical chemistry, and the development of radiopharmaceuticals and nanoparticles containing radioisotopes for radionuclide therapy and molecular imaging. |
| Education and main positions held | Education: 2003: Ph.D. in Chemistry from the University of Rennes 1. 2003: Dottorato di Ricerca in Scienze Chimiche from the University of Ferrara (Italy). 2000: Engineer from the Ecole Nationale Supérieure de Chimie de Rennes (ENSCR). 2000: DEA (Master degree) in Fine Chemistry – Syntheses and Production; University of Rennes 1/ENSCR. Current position: Radiopharmaceutical Scientist in the Pharmacy Department of the Comprehensive Cancer Centre Eugène Marquis, in Rennes, France |
| Current projects | Current projects include: 1) Development of 188Re- and 90Y-labelled Lipiodol (radioembolisation of liver cancers). 2) Development of radiolabelled tumor-specific peptides, its radiolabelling, and its use for targeting radiolabelled nanoparticles. 3) Development of radiolabelled nanoparticles. 4) Study of tumor and microenvironmental responses after radionuclide therapy. |
| Selected publications | – E. Garin, X. Palard, Y. Rolland, S. Le Sourd, N. Lepareur, V. Ardisson, C. Bouvry, S. Laffont, B. Campillo-Gimenez, E. Bellissant, J. Edeline, 188Re-SSS lipiodol radioembolization in HCC patients: results of a Phase 1 trial (Lip-Re-01 study), Cancers, 2023, 15, 2245. doi: 10.3390/cancers15082245. – N. Lepareur, M. Bourgeois, Receptor-Specific Radionuclide Therapy. in Handbook of Cancer and Immunology, N. Rezaei Eds., Springer, Cham, 2022. doi: 10.1007/978-3-030-80962-1_303-1. – N. Lepareur. Cold kit labeling: the future of 68Ga-radiopharmaceuticals? Frontiers in Medicine – Nuclear Medicine, 2022, doi: 10.3389/fmed.2022.812050. – C. Brossard, M. Vlach, E. Vène, C. Ribault, V. Dorcet, N. Noiret, P. Loyer, N. Lepareur, S. Cammas-Marion. Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells. Nanomaterials, 2021, 11, 958. doi: 10.3390/nano11040958. – N. Lepareur, F. Lacœuille, C. Bouvry, F. Hindré, E. Garcion, M. Chérel, N. Noiret, E. Garin, F. F. (Russ) Knapp Jr, Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives, Frontiers in Medicine – Nuclear Medicine, 2019, doi: 10.3389/fmed.2019.00132. – M. Le Fur, M. Beyler, E. Molnar, O. Fougere, D. Esteban-Gómez, G. Tircsó, C. Platas-Iglesias, N. Lepareur, O. Rousseaux, R. Tripier, Role of the capping bond effect on pyclen natY3+/90Y3+ chelates: full control of the regiospecific N-functionalisation makes the difference, Chem. Commun., 2017, 53, 9534-9537. – D. Séhédic, I. Chourpa, C. Tétaud, A. Griveau, C. Loussouarn, S. Avril, C. Legendre, N. Lepareur, D. Wion, F. Hindré, F. Davodeau, E. Garcion, Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma, Theranostics, 2017, 7, 4517-4536. – N. Lepareur, L. Leal E Costa, M. Bocqué, C. Blondelle, C. Ruello, M. Desjulets, N. Noiret, S. Cammas-Marion, Development of biocompatible and functional polymeric nanoparticles for site-specific delivery of radionuclides, Frontiers in Medicine – Nuclear Medicine, 2015, 2:63. doi: 10.3389/fmed.2015.00063. |